Key Highlights
- $80 million funding secured from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher.
- Investment to expand AI disease models and establish a new office in Cambridge, MA.
- Technology enhances R&D decisions, improving speed and accuracy in pharma.
- Top six pharma companies utilize CytoReason’s AI-driven insights.
- Significant scientific contributions published in top-tier journals.
Source: Business Wire
Notable Quotes
- “CytoReason is grateful for this infusion of new capital from industry technology powerhouses such as NVIDIA, Pfizer, and Thermo Fisher. The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling. CytoReason is at the forefront of this revolution in pharma R&D.” — David Harel, Co-founder and CEO at CytoReason
- “Over the last year, CytoReason has strengthened its platforms using NVIDIA’s latest accelerated computing and AI platforms, achieving more than 10x acceleration for inference workloads. Our continued collaboration with CytoReason will help enable more life sciences companies to benefit from CytoReason’s predictive clinical insights.” — Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA
- “The rapid expansion of new technologies, like artificial intelligence, holds tremendous potential to help transform what is possible in human health. Our collaboration with CytoReason leverages its cutting-edge immunology multiomics platform to augment Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients.” — Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer
SoHC's Take
CytoReason’s recent $80 million investment marks a significant milestone in the advancement of computational disease models within the pharmaceutical industry. This substantial funding from prominent investors like OurCrowd, NVIDIA, Pfizer, and Thermo Fisher demonstrates the growing recognition of AI-driven insights in revolutionizing pharma R&D. CytoReason’s technology not only enhances the speed and accuracy of R&D decisions but also contributes to personalized healthcare, ultimately benefiting patients worldwide. The establishment of a new office in Cambridge, MA, and the expansion of its disease models into additional indications, positions CytoReason as a leader in the next wave of biopharma innovation.
